Koa Shoji Holdings (9273) Q2 2025 earnings summary

Executive summary

• H1 FY2025 revenue rose 7.7% YoY to ¥12,259 million; operating profit increased 28.0% to ¥3,063 million and net income attributable to owners of the parent rose 31.1% to ¥2,049 million.

• API and pharmaceutical segments both recorded higher revenue and operating profit, supported by increased API volumes and improved pharmaceutical manufacturing productivity.

• Earnings per share increased to ¥48.66 from ¥39.46 YoY.

Financial highlights

• Gross profit rose 20.2% YoY to ¥4,157 million; the cost ratio improved 3.5 percentage points as sales increased ¥877 million.

• Ordinary profit increased 25.6% YoY to ¥3,065 million.

• Comprehensive income was ¥2,053 million, up from ¥1,537 million YoY.

Outlook and guidance

• FY2025 guidance was unchanged: revenue ¥23,350 million, up 5.5% YoY; operating profit ¥4,620 million, up 5.4%; net income attributable to owners of the parent ¥3,080 million, up 4.5%.

• FY2025 ordinary profit is forecast at ¥4,600 million and EPS at ¥73.13.

• Segment forecasts: external API sales ¥14,690 million, up 7.0%; pharmaceutical sales ¥8,660 million, up 3.1%.